Eval GRADE ECA CATT: Ranibizumab vs Bevacizumab para degeneración macular neovascular asociada a la edad. [Martin et al, 2011]
Grupo Evalmed
DESCARGAR PDF:
Eval GRADE ECA CATT 1y, ranibizumab vs bevacizumab, DMAE
Eval GRADE ECA CATT 1y, ranibizumab vs bevacizumab, DMAE